PEG MGF

Identity and composition

PEG-MGF (Pegylated Mechano Growth Factor) is the pegylated form of a synthetic peptide derived from the E domain of Mechano Growth Factor (MGF), described in the literature as a splice variant of the IGF-1 gene (IGF-1Ec in humans). It is studied in preclinical research on skeletal muscle biology. Product for research use.

As for its chemical identity, the usual reference constants (CAS number, molecular weight, molecular formula, and amino-acid sequence) could not be confirmed in public databases such as PubChem or DrugBank and are therefore deliberately omitted from this data sheet so as not to publish unverified data. The values circulating in supplier catalogs have not been confirmed in primary sources and are not reproduced here.

Among its synonyms documented ones include: Pegylated Mechano Growth Factor, PEG MGF, Mechano Growth Factor (pegylated) and MGF (IGF-1Ec E-domain peptide), PEGylated. The prefix "PEG" refers to pegylation, a general strategy of conjugation with polyethylene glycol.

Mechanism of action

El Mechano-Growth Factor (MGF) is described in the literature as a splice variant of the IGF-1 gene (IGF-1Ec in humans, IGF-IEb in rodents) whose expression increases locally in skeletal muscle after mechanical load or damage. The mechanistic hypothesis, based on the synthetic peptide of the E domain (the unique C-terminal region of unprocessed IGF-1), proposes the activation and proliferation of muscle satellite cells in a quiescent state without inducing their premature differentiation (Matheny 2010; PMID 20130113).

At the signaling level, it has been reported that the synthetic MGF peptide induces ERK phosphorylation without Akt activation and it is proposed to act independently of the classical IGF-1 receptor (IGF-IR), which would distinguish it from mature IGF-1 (Matheny 2010; PMID 20130113).

Important warning: this mechanism is a subject of debate. A peer-reviewed mini-review notes that definitive evidence for the MGF hypothesis is lacking and that no endogenous peptide analog produced by the Igf1 gene has been isolated from cells or tissue (Matheny 2010; PMID 20130113). In addition, a controlled study observed that the MGF peptide, up to 500 ng/ml, did not increase the proliferation of C2C12 myoblasts or of primary human myoblasts, and did not inhibit differentiation (Fornaro 2014; PMID 24253050). No peer-reviewed pharmacology specific to the pegylated construct was located.

Pharmacokinetics

None were found verified pharmacokinetic data of PEG-MGF in the primary literature. The claims that native MGF would have a very short half-life (minutes) and that pegylation would extend it to days appear only in supplier or secondary sources, and could not be confirmed against a peer-reviewed or regulatory source; they should be treated as not verified.

In qualitative terms and as a general framework, pegylation is a strategy employed to prolong the half-life of peptides and proteins, but no specific pharmacology of the pegylated construct of MGF was found that would allow quantifying this effect.

Scientific evidence

The available evidence is preliminary and preclinical in nature, limited to cell culture and animal models; no clinical trials in humans were identified for PEG-MGF or for MGF on ClinicalTrials.gov. The published work focuses on the endogenous splicing of MGF/IGF-1Ec and on the effects of the synthetic E-domain peptide, in the context of skeletal muscle regeneration and satellite cell biology.

The biological activity of MGF itself is actively debated in the literature: its role in tissue repair and regeneration has been proposed, but a mini-review concludes that definitive evidence is lacking and that the endogenous peptide has not been isolated (Matheny 2010; PMID 20130113). A controlled study did not reproduce the proliferative effect of the synthetic peptide on myoblasts (Fornaro 2014; PMID 24253050).

The specific pegylated variant ("PEG-MGF") appears predominantly in supplier and research-reagent listings rather than in indexed primary literature, so any claim about it must be considered unproven.

Research applications

Product for research use. PEG-MGF is offered exclusively as a reagent for laboratory studies.

It may be of interest for research in:

• In vitro studies of satellite cell and myoblast biology (e.g., proliferation and differentiation assays).
• Exploratory research on IGF-1 splice variants and the E domain of MGF.
• Preclinical models of skeletal muscle regeneration, in an experimental context.

Not applicable for:

• clinical use, therapeutic use, diagnostic or preventive.
• Clinical use or use in patients: it is not an approved drug and there are no clinical trials supporting indications.
• Any application outside a research environment controlled by trained personnel.

Research protocols

There are no established dosing protocols for PEG-MGF, since no clinical trials or primary pharmacology of the pegylated construct were identified. Any scheme circulating in supplier sources lacks support in peer-reviewed literature and is not reproduced here.

As the only concentration data coming from a controlled study, and by way of an in vitro experimental reference (not as a usage guideline), it has been reported that the MGF peptide was evaluated in cell culture at concentrations of up to 500 ng/ml, with no observed increase in proliferation of C2C12 or human primary myoblasts (Fornaro 2014; PMID 24253050). This value corresponds to a cell-culture context and does not constitute a dose for animal models or for any other use.

Reconstitution

As general laboratory handling guide, lyophilized peptides are usually reconstituted with bacteriostatic water (water for injection with approximately 0.9% benzyl alcohol as preservative), which is suitable for multi-use vials.

General technique guideline:

• Let the lyophilized vial and the diluent reach room temperature before handling them.
• Add the solvent letting it run slowly down the inner wall of the vial, without injecting directly onto the powder.
• Do not shake: swirl the vial gently until complete dissolution so as not to damage the peptide.
• The solvent volume is chosen according to the working concentration desired for the experimental protocol.

This guide is qualitative and standard for the laboratory; it does not imply suitability for any use in humans.

Stability and storage

As general handling standard of research peptides:

• Lyophilized (powder): usually retains its stability better when stored frozen and protected from light and moisture; it is the most stable form for long-term storage.
• Reconstituted (in solution): once dissolved, it is usually kept under refrigeration and its use is recommended within a short time, avoiding repeated freeze-thaw cycles that can degrade the peptide.

It is advisable to divide into aliquots when the protocol allows it in order to minimize thaw cycles. These are qualitative laboratory practices; no specific verified stability data were found for PEG-MGF in primary sources.

Safety profile

No documented safety data were found for PEG-MGF in primary or regulatory sources: there is no published adverse-event profile, no regulatory safety evaluation, and no human safety data.

PEG-MGF is not an approved drug and its classification is for research use only. As there is no verified toxicological or tolerability information, it must be handled with the general precautions applicable to any research reagent with an uncharacterized profile, by trained personnel and with appropriate protective equipment. No documented contraindications are available because no studies exist that have established them.

Comparative context

Compared with the mature or full-length IGF-1, which signals through the IGF-1R receptor to drive protein synthesis and myoblast differentiation, the MGF E-domain peptide is proposed to act via a distinct route, independent of IGF-1R, which would favor satellite cell proliferation over differentiation.

Within the splice isoforms of IGF-1, the upregulation of IGF-IEb/MGF is associated with proliferation markers, while the IGF-IEa isoform is associated with differentiation toward mature myofibers.

It is important to qualify this comparison: the direct proliferative effect attributed to the synthetic peptide was not reproduced in a controlled study (Fornaro 2014; PMID 24253050), so the functional distinction between MGF and IGF-1 remains a matter of debate in the literature.

History and development

MGF emerges in the scientific literature as a splice variant of the IGF-1 gene (termed IGF-1Ec in humans and IGF-IEb in rodents), whose local expression in skeletal muscle was described as associated with mechanical load and tissue damage. From this observation a peptide corresponding to the E domain, the unique C-terminal region of unprocessed IGF-1, to study its effects in cell culture and animal models within the field of muscle regeneration and satellite cell biology.

The MGF hypothesis has been questioned: a mini-review noted the absence of definitive evidence and of isolation of the endogenous peptide (Matheny 2010; PMID 20130113). The variant pegylated ("PEG-MGF") appears mainly in supplier and research reagent listings, with no specific published primary pharmacology, so its documented development is limited and it should be treated as unproven.

FAQ

Customer reviews

Average rating: 5.0 out of 5, based on 4 customer ratings.

Scientific references (6)

Peer-reviewed literature on PEG MGF, with its PubMed identifier when available:

• Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages (Kandalla, et al. · Mechanisms of Ageing and Development · 2011) PMID 21354439.
• Pretreatment with mechano growth factor E peptide attenuates osteoarthritis through improving cell proliferation and extracellular matrix synthesis in chondrocytes under severe hypoxia (Sha, et al. · International Immunopharmacology · 2021) PMID 34015701.
• The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men. (Hameed M, et al. · J Physiol · 2004) PMID 14565994.
• Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro. (Philippou A, et al. · In Vivo · 2009) PMID 19567392.
• Effects of eccentric cycling exercise on IGF-I splice variant expression in the muscles of young and elderly people. (Hameed M, et al. · Scand J Med Sci Sports · 2008) PMID 18067523.
• Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. (Yang SY, et al. · FEBS Lett · 2002) PMID 12095637.

Other related research peptides

• Tesamorelin
• Tesamorelin + Ipamorelin
• VIP
• Sermorelin acetate
• B7-33
• CJC-1295 (DAC)
• CJC-1295 (Without DAC)
• CJC-1295 (No DAC) + Ipamorelin
• GHRP-2
• GHRP-6